Search

Author/Creator Climent Duran, Miguel Angel

1. Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. Issue 9 (20th March 2021)

Authors:
McDermott, David F.; Lee, Jae-Lyun; Bjarnason, Georg A.; Larkin, James M. G.; Gafanov, Rustem A.; Kochenderfer, Mark D.; Jensen, Niels Viggo; Donskov, Frede; Malik, Jahangeer; Poprach, Alexandr; Tykodi, Scott S.; Alonso-Gordoa, Teresa; Cho, Daniel C.; Geertsen, Poul F.; Climent Duran, Miguel Ange...
Journal:
Journal of clinical oncology
Issue:
Volume 39:Issue 9(2021)
Page Start:
1020
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib. (19th April 2021)

Authors:
de Velasco, Guillermo; Ruiz‐Granados, Álvaro; Reig, Oscar; Massari, Francesco; Climent Duran, Miguel Angel; Verzoni, Elena; Graham, Jeffrey; Llarena, Roberto; De Tursi, Michele; Donskov, Frede; Iglesias, Clara; Pandha, Hardev S.; Garcia del Muro, Xavier; Procopio, Giuseppe; Oudard, Stephane; Cast...
Journal:
BJU international
Issue:
Volume 128:Number 2(2021)
Page Start:
254
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9 (September 2022)

Authors:
Powles, Thomas; Tomczak, Piotr; Park, Se Hoon; Venugopal, Balaji; Ferguson, Thomas; Symeonides, Stefan N; Hajek, Jaroslav; Gurney, Howard; Chang, Yen-Hwa; Lee, Jae Lyun; Sarwar, Naveed; Thiery-Vuillemin, Antoine; Gross-Goupil, Marine; Mahave, Mauricio; Haas, Naomi B; Sawrycki, Piotr; Burgents, Jo...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 9(2022)
Page Start:
1133
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗